According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

At only seven years old, Tabib was diagnosed with acute myeloid leukemia, a diagnosis that forever changed her life.

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...